China’s pharmaceutical contractors are showing financial resilience in the face of Washington’s push to curb reliance on Chinese supply chains.
Genscript Biotech raised its full-year guidance for its life science service segment, covering DNA, RNA and peptide synthesis tools alongside protein production services, to a range of 25 to 30 per cent for the full year. The segment accounts for most of its revenue.
AI-driven drug discovery orders were expected to “double in the second half” and would remain strong over the next several years, chief financial officer Phil Zhou said on an earnings call.


Don't Miss:
-
FBI Most Wanted “Chapo Isidro,” Leader of BLO/Guasave Cartel Arrested in Sinaloa, “El Musico” Possibly Killed
-
DEA’s #FugitiveFriday asks for tips on “El Tano” García Corrales, found dead in Sinaloa in 2024
-
Mocorito, Sinaloa: “El Pagador” and “El Chendo” of La FEA, arrested again 15 months after walking free
-
Zapopan: Marines arrest “El Topo,” alleged Los Deltas leader linked to journalist’s kidnapping; three gunmen killed
-
Anabel Hernández claims “El Mayito Gordo” is back in Mexico, fighting Los Chapitos from the Durango sierra

Trump Enjoyed His Asian Spectacle. He Came Home Empty-Handed
Medical device makers have gotten worse at disclosing when their products harm people, new study finds. The FDA let them.
Anatomy of a Chinese loanbook